ES2107422T3 - Moleculas de adn recombinante, huespedes, procedimientos y polipeptidos similares a proteinas portadoras de somatomedina humana. - Google Patents

Moleculas de adn recombinante, huespedes, procedimientos y polipeptidos similares a proteinas portadoras de somatomedina humana.

Info

Publication number
ES2107422T3
ES2107422T3 ES90901407T ES90901407T ES2107422T3 ES 2107422 T3 ES2107422 T3 ES 2107422T3 ES 90901407 T ES90901407 T ES 90901407T ES 90901407 T ES90901407 T ES 90901407T ES 2107422 T3 ES2107422 T3 ES 2107422T3
Authority
ES
Spain
Prior art keywords
dna molecules
polypeptides
carrier protein
human
hosts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90901407T
Other languages
English (en)
Inventor
Emerald Martin Spencer
Carol Talkington-Verser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23115154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2107422(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2107422T3 publication Critical patent/ES2107422T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ESTA INVENCION SE REFIERE A POLIPEPTIDOS QUE SON SUBUNIDADES DE PROTEINA QUE TRANSPORTAN SOMATOMEDINA HUMANA, Y A PROCESOS PARA PRODUCIRLOS. LAS SUBMIDADES DE PROTEINA TRANSPORTADORA SE UNEN A POLIPEPTIDOS EN FORMA DE PROTEINA HUMANA, TAMBIEN CONOCIDOS COMO FACTORES DE CRECIMIENTO DE TIPO DE INSULINA. EL PROCESO INCLUYE LA PREPARACION A PARTIR DE UNA FRACCION DE SUERO HUMANO, COHN+V-1, POR UNA MOLECULA DE VARIOS PASOS CROMATOGRAFICOS. ESTA INVENCION TAMBIEN SE REFIERE A MOLECULAS DE ADN QUE CODIFICAN POLIPEPTIDOS EN FORMA DE PROTEINA TRANSPORTADORES DE SOMATOMEDINA HUMANA, MOLECULAS DE ADN RECOMBINANTES, RECEPTORES, PROCESOS PARA PRODUCIR POLIPEPTIDOS EN FORMA DE PROTEINA TRANSPORTADORA, POLIPEPTIDOS EN FORMA DE PROTEINA TRANSPORTADORES DE SOMATOMEDINA HUMANA PRODUCIDOS UTILIZANDO AQUELLAS MOLECULAS, RECEPTORES Y PROCESOS. LA INVENCION SE REFIERE A MOLECULAS DE ADN Y SU EXPRESION EN RECEPTORES APROPIADOS. LAS MOLECULAS DE ADN RECOMBINANTES CONTIENEN MOLECULAS DE ADN QUE CODIFICAN PARA POLIPEPTIDOS QUE TIENEN UNA ACTIVIDAD BIOLOGICA DE LA PROTEINA TRANSPORTADORA HUMANA O UNA SUBUNIDAD DE PROTEINA TRANSPORTADORA HUMANA CAPAZ DE LIGAR SOMATOMEDINAS. LAS MOLECULAS DE ADN, MOLECULAS DE ADN, RECOMBINANTES, RECEPTORES Y PROCESOS DE ESTA INVENCION PUDEN UTILIZARSE EN LA PRODUCCION DE POLIPEPTIDOS UTILES PARA VARIAS APLICACIONES TERAPEUTICAS, DIAGNOSTICOS Y OTRAS APLICACIONES UTILES.
ES90901407T 1988-12-22 1989-12-21 Moleculas de adn recombinante, huespedes, procedimientos y polipeptidos similares a proteinas portadoras de somatomedina humana. Expired - Lifetime ES2107422T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29025088A 1988-12-22 1988-12-22

Publications (1)

Publication Number Publication Date
ES2107422T3 true ES2107422T3 (es) 1997-12-01

Family

ID=23115154

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90901407T Expired - Lifetime ES2107422T3 (es) 1988-12-22 1989-12-21 Moleculas de adn recombinante, huespedes, procedimientos y polipeptidos similares a proteinas portadoras de somatomedina humana.

Country Status (14)

Country Link
EP (2) EP0375438A3 (es)
JP (2) JPH04503352A (es)
KR (1) KR910700261A (es)
AT (1) ATE155793T1 (es)
AU (1) AU4836890A (es)
CA (1) CA2006322C (es)
DE (1) DE68928203T2 (es)
DK (1) DK95291A (es)
ES (1) ES2107422T3 (es)
GR (1) GR3025094T3 (es)
HK (1) HK1000826A1 (es)
IL (1) IL92816A0 (es)
WO (1) WO1990006950A1 (es)
ZA (1) ZA899832B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
AU713275B2 (en) * 1994-07-20 1999-11-25 Celtrix Pharmaceuticals, Inc. IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
DK1141015T3 (da) 1999-01-06 2010-01-25 Genentech Inc Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
AU2002248609B2 (en) 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
CA2538342C (en) 2003-09-12 2013-01-08 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
EP1670822A2 (en) 2003-10-03 2006-06-21 Genentech, Inc. Igf binding proteins
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
CA2641310C (en) 2006-02-03 2013-08-20 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
JP2020533344A (ja) 2017-09-11 2020-11-19 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 慢性肺疾患を治療するための方法および組成物
CA3194764A1 (en) 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions suitable for use in neonates
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
IL89661A (en) * 1988-03-17 1999-05-09 Novo Nordisk As Heparin binding proteins
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
JPH03504597A (ja) * 1988-04-12 1991-10-09 シナージェン，インコーポレーテッド インスリン様成長因子活性の強化および阻害方法

Also Published As

Publication number Publication date
EP0451194B1 (en) 1997-07-23
CA2006322C (en) 2000-08-01
CA2006322A1 (en) 1990-06-22
DE68928203T2 (de) 1998-01-15
AU4836890A (en) 1990-07-10
ATE155793T1 (de) 1997-08-15
DK95291D0 (da) 1991-05-21
JPH11236400A (ja) 1999-08-31
IL92816A0 (en) 1990-09-17
DK95291A (da) 1991-08-16
JPH04503352A (ja) 1992-06-18
ZA899832B (en) 1990-10-31
GR3025094T3 (en) 1998-01-30
EP0375438A2 (en) 1990-06-27
EP0451194A1 (en) 1991-10-16
EP0451194A4 (en) 1992-09-02
DE68928203D1 (de) 1997-09-04
HK1000826A1 (en) 1998-05-01
WO1990006950A1 (en) 1990-06-28
KR910700261A (ko) 1991-03-14
EP0375438A3 (en) 1992-03-25

Similar Documents

Publication Publication Date Title
ES2107422T3 (es) Moleculas de adn recombinante, huespedes, procedimientos y polipeptidos similares a proteinas portadoras de somatomedina humana.
DK677688D0 (da) Humane somatomedinbaererproteinunderenheder og fremgangsmaade til fremstilling af saadanne
DE721983T1 (de) Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
DE3783191D1 (de) Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g.
IL92257A0 (en) Binding proteins for insulin-like growth factors,pharmaceutical compositions containing them and dna fragments encoding them
DE69637148D1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
FI103892B1 (fi) Rekombinantti-DNA-molekyyli, joka koodaa polypeptidiä/proteiinia, jolla on oleellisesti vaskulaaristen antikoaguloivien proteiinien biologiset ominaisuudet sekä niiden valmistus
DE3855084D1 (de) Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist
ATE290087T1 (de) Neue signalsequenzen
FI921600A (fi) Bjoerkpollenallergen p14 foer diagnos och behandling av allergiska sjukdomar.
PT98804A (pt) Processo de preparacao de igfbp-4 ou um fragmento da mesma
CA2128215C (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
WO1995008628A3 (en) Nucleic acids encoding merosin, merosin fragments and uses thereof
DK595187D0 (da) Minactivin og fremgangsmaade til fremstilling deraf
IL78278A0 (en) Process for the production of polypeptides,dna sequence encoding desired polypeptide human somatomedin c polypeptide and recombinant dna molecules
Spencer et al. Uses for antibodies which bind to human somatomedin carrier protein subunits

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 451194

Country of ref document: ES